Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)

• Status: Completed
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study addresses a "lifespan approach to healthy development and aging" with direct relevance to humans by testing the anti-aging effects of acarbose in humans. It is a pilot study to: i) better estimate power for a larger trial, ii) establish the safety and potential beneficial effects of acarbose in non-diabetic elderly humans, and iii) determine whether the effects of acarbose on the microbiome likely play a role in its enhancement of longevity and/or healthy aging. These are essential initial steps for translating acarbose into an anti-aging human therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The University of Texas Health Science Center at San Antonio
• Treatments: Acarbose

Criteria

Inclusion Criteria:

• age 70-95

• participants will be in good health with all chronic diseases (hypertension, coronary artery disease, etc.) clinically stable.

• participants must have adequate cognitive function to be able to give informed consent. This will be established by enrolling participants with CLOX 1 scores of ≥10.

Exclusion Criteria:

• unstable ischemic heart disease

• clinically significant pulmonary disease

• history of immunodeficiency or receiving immunosuppressive therapy

• history of a coagulopathy or receiving a medical condition requiring anticoagulation

• an estimated glomerular filtration rate of <30ml/min

• uncontrolled hypercholesteremia >350mg/dl;

• uncontrolled hypertriglyceridemia >500mg/dl

• diabetes

• history of skin ulcers or poor wound healing

• smoking

• liver disease treatment with drugs known to affect cytochrome P450 3A (diltiazem, erythromycin)